A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers

NCT04603040 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy

Interventions

DRUG: Toripalimab

Sponsor

Shanghai Junshi Bioscience Co., Ltd.